Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ASX:CTD
ASX:CTDHospitality

Does the ASX Suspension and Accounting Probe Change the Bull Case for Corporate Travel Management (ASX:CTD)?

In recent weeks, Corporate Travel Management was suspended from the Australian Stock Exchange after disclosing accounting irregularities that prompted a delay in releasing its financial results and ongoing investigations by Deloitte and KPMG. This development puts a spotlight on financial transparency and the importance of timely, accurate reporting within the travel services sector, especially as the company manages a substantial £550 million UK government contract. We'll examine how the...
ASX:PLS
ASX:PLSMetals and Mining

How the Recent Lithium Price Rebound Is Shaping Pilbara Minerals’ Valuation in 2025

Trying to figure out what to do with Pilbara Minerals’ stock right now? You’re not alone. Over the past month, the share price has bounced back, climbing over 11.6%. That jump follows a 6.6% rise just this past week, hinting that investors might be spotting new reasons for optimism, or maybe they’re rethinking the risks around lithium exposure in today’s shifting market. Of course, the bigger picture includes some sobering moves: a 1-year dip of 18.3%, and a steeper 44% slide over 3 years,...
ENXTPA:ODET
ENXTPA:ODETLogistics

How the Recent 4.9% Drop Impacts Compagnie de l'Odet's Valuation in 2025

Thinking about whether to hold or buy more Compagnie de l'Odet stock this year? You are definitely not alone. Over the past few years, this French conglomerate has kept investors on their toes, thanks in part to its quietly impressive long-term story. Despite wider market swings and shifting investor sentiment, the stock has delivered a remarkable 108.2% growth over the last five years. But before you get too comfortable, the ride has not been all smooth. The past year has seen shares drop by...
TSX:MEG
TSX:MEGOil and Gas

Is MEG Energy Fairly Priced After Its Exceptional Five Year Performance in 2025?

If you have been eyeing MEG Energy and wondering whether now is the right time to make a move, you are not alone. This stock has had quite a journey, turning heads with a staggering 961.4% return over the past five years. Even if you zoom in a little closer, the numbers are impressive: up 94.8% over three years, with a healthy 18.0% gain year to date. Yet, the recent mood has been a touch more cautious, with the stock dipping -2.4% over the past week, despite not much in the way of major news...
TASE:FIBI
TASE:FIBIBanks

What Recent Regulatory Discussions Mean for First International Bank of Israel’s Share Price in 2025

Thinking about what’s next for First International Bank of Israel stock? You’re not alone. With a stellar 53.4% gain over the past year and an astonishing 301.6% surge over the last five years, plenty of investors are wondering if there’s still room to run or if things are getting a bit overheated. The recent 21.7% jump year-to-date reflects ongoing optimism. However, there was a minor pullback this past month, down 4.6%, and a slight dip of 1.4% over the last week. These short-term changes...
OTCPK:AFIP.A
OTCPK:AFIP.AInsurance

AMFI (OTCPK:AFIP.A): Assessing Valuation After Sustained Long-Term Gains and Recent Market Quiet

AMFI (OTCPK:AFIP.A) may not always grab headlines, but its recent moves in the market have investors wondering what the next chapter might hold. There’s no major headline event or explosive news to explain recent activity, and that in itself brings an intriguing question: is the current share price momentum sending a subtle signal, or is it simply business as usual for a company flying under the radar? Looking at the past few months, AMFI’s share price hasn’t budged—flat over the past week...
NasdaqGS:GH
NasdaqGS:GHHealthcare

What Catalysts Are Changing the Narrative for Guardant Health?

Guardant Health's consensus analyst price target saw only a slight increase in the most recent update, moving from $61.33 to $62.41. This relatively stable price expectation reflects strong revenue momentum and continued leadership in liquid biopsy technology. It also shows tempered optimism following recent clinical data results. Read on to discover what is driving these perspectives and how you can stay informed about evolving developments for Guardant Health moving forward. What Wall...
ASX:DUG
ASX:DUGSoftware

DUG Technology (ASX:DUG) Valuation: Assessing Recent Contract Wins and Capital Raise

DUG Technology (ASX:DUG) just gave markets plenty to talk about. In a double dose of news, the company announced the quotation of 436,738 new ordinary shares on the ASX, aimed at boosting liquidity and broadening its reach. Additionally, it secured the first purchase order from Petronas under a multi-year contract, with the overall value of the deal climbing higher than first expected. For investors keeping an eye on the tech sector, these moves signal a company actively expanding both its...
TSX:ORA
TSX:ORAMetals and Mining

Aura Minerals (TSX:ORA): Evaluating Valuation After Borborema Gold Mine Achieves Commercial Production

If you’ve been tracking Aura Minerals (TSX:ORA) lately, you likely noticed the recent excitement after the company announced it hit commercial production at its Borborema gold mine. With the mill now running above 80% of its design capacity and gold recoveries climbing past 90%, this moment marks a tangible boost for Aura’s future production profile. Investors watching for concrete signs that Aura can deliver on its ambitious growth promises finally have a new data point to factor into their...
NasdaqGM:AVDL
NasdaqGM:AVDLPharmaceuticals

Why The Story Around Avadel Pharmaceuticals Is Evolving After Recent Analyst and Market Updates

Avadel Pharmaceuticals recently saw its consensus analyst price target edge up slightly from $20.20 to $20.30, reflecting a largely steady outlook. This minimal change is rooted in a balance between optimism over Lumryz’s commercial momentum and lingering concerns about ongoing competition in the sleep disorder market. Read on to discover how you can stay informed about ongoing shifts in the stock's narrative as new developments unfold. What Wall Street Has Been Saying Analyst commentary on...
NasdaqGS:CLBT
NasdaqGS:CLBTSoftware

How the Narrative Surrounding Cellebrite Is Shifting Amid Federal Delays and Future Catalysts

Cellebrite DI's consensus analyst price target has seen a modest uptick, rising from $22.57 to $23.14 despite several headwinds. While lingering softness in the U.S. federal market and revised revenue estimates have tempered enthusiasm, analysts attribute much of this to deal timing delays rather than a loss of demand. Stay tuned to find out how you can track ongoing developments in Cellebrite DI's evolving story. What Wall Street Has Been Saying Analyst coverage of Cellebrite DI reflects a...
TSX:SVM
TSX:SVMMetals and Mining

What Catalysts Are Changing the Story for Silvercorp Metals Now?

Silvercorp Metals stock has recently seen its consensus analyst price target rise from CA$8.38 to CA$8.76, reflecting a renewed sense of optimism among market watchers. This uptick is driven by expectations of production growth, leverage to stronger silver prices, and the upcoming diversification of assets. Read on to discover how you can follow these evolving developments and stay informed about Silvercorp Metals’ shifting narrative. What Wall Street Has Been Saying Analyst coverage of...
XTRA:NOEJ
XTRA:NOEJMachinery

NORMA Group (XTRA:NOEJ) Is Down 7.9% After Cutting 2025 Sales Forecast Following Water Unit Sale – Has The Bull Case Changed?

On September 23, 2025, NORMA Group SE issued revised earnings guidance, lowering its expected group sales from continuing operations for the year to approximately €810 million to €830 million, down from its previous estimate, which included Water Management, of around €1.1 billion to €1.2 billion. This updated forecast reflects NORMA Group’s realignment of its business focus and the anticipated effects of its divestment of the Water Management unit, offering insight into management’s current...
OM:ARJO B
OM:ARJO BMedical Equipment

Arjo (OM:ARJO B): Exploring Valuation Opportunities After a Quiet Period in Share Price Movement

There has not been a particular event sending shockwaves through Arjo (OM:ARJO B) shares this week, but sometimes a quieter period can be just as interesting. Investors keeping an eye on the medical technology maker may be wondering if recent market movements signal something deeper, such as shifting expectations for growth or profitability. Valuation becomes an important consideration, especially as the company continues to recalibrate in a changing healthcare environment. Taking a step...
TSX:BDI
TSX:BDICommercial Services

3 TSX Growth Stocks With Up To 24% Insider Ownership

As the Canadian market navigates a period of uncertainty, with central banks offering limited guidance on future policy moves, investors are closely monitoring economic indicators and their impact on major indices. In this environment of potential volatility, growth companies with high insider ownership can be particularly appealing due to the alignment of interests between company insiders and shareholders.
NasdaqGS:PFIS
NasdaqGS:PFISBanks

Exploring 3 Undervalued Small Caps With Insider Buying In The Global Market

As the U.S. stock market experiences a downturn led by declines in tech shares, small-cap stocks present an intriguing opportunity for investors navigating the current economic landscape shaped by recent Federal Reserve rate cuts. In this environment, identifying small-cap companies with strong fundamentals and insider buying can be key to uncovering potential value amidst broader market fluctuations.